Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders

Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders

BackgroundsIntramuscular injection of the SARS-CoV-2 vaccine has raised concerns about its use in patients with neuromuscular disorders (NMDs). We evaluated the response of patients with NMDs to the BNT162b2 vaccine.MethodsHealthy subjects, patients with spinal muscular atrophy (SMA), and patients w...

Full description

Bibliographic Details
Main Authors: Hideyuki Iwayama, Naoko Ishihara, Kohei Kawahara, Yuta Madokoro, Yasuko Togawa, Kanji Muramatsu, Ayuka Murakami, Satoshi Kuru, Toshiyuki Kumagai, Wataru Ohashi, Kengo Nanya, Shinji Hasegawa, Masahisa Katsuno, Akihisa Okumura
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
neuromuscular disorders
SARS-CoV-2
vaccination
spinal muscular atrophy
Duchenne muscular dystrophy
residual muscle volume
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.996134/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.996134/full

Similar Items